Why Doesn't Tirzepatide Work for Me? (October 2026)

01 · The short answer

Why tirzepatide can seem not to work

Tirzepatide seems not to work for most people because the dose, the timeline or the habits around it do not yet match what the medicine needs. It is a once-weekly prescription medicine used alongside a reduced-calorie diet and increased physical activity, so it supports those changes rather than replacing them.¹ That framing explains most disappointment: the pen reduces appetite, but the overall result still depends on what happens at the table across many weeks.

The honest picture has two sides. Many people respond well, and the trials show large average losses. But averages hide a wide range, and some people lose more slowly than others for reasons that are not always obvious.

02 · Your next step

The two decisions you are actually facing

The first decision is whether this is a timing problem or a response problem. If you are early in treatment, still on a low strength, or recently plateaued, it is almost certainly timing. Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest; most measurable progress builds from 5mg onward, month by month.² If you have been through the full dose ladder and tolerated a higher strength for a good stretch with little change, that is a different conversation.

The second decision is what to do next. Bring what you find to your prescriber, because they can see your dose history, side effects and progress together. If you are an existing customer, our monthly reviews are built for exactly this. If you are still weighing up treatment, our weight loss clinic explains how a consultation works, and the Mounjaro pen page shows live prices for every strength.

A plateau is not a reason to double doses or add unlicensed products. Changes belong with your prescriber, within the licence.

03 · Self-check

A quick self-check before you worry

Ask yourself five plain questions. Have I given the current dose enough time? Am I measuring the trend rather than single weigh-ins? Have my portions, snacks and drinks quietly crept back up? Am I eating enough protein and staying active? Are sleep and alcohol working against me? If you can answer yes to the first two and honestly no to some of the others, you have found your starting point.

If everything checks out and progress is still slow, that is useful information to share rather than a reason to quit.

04 · What 'not working' means

What 'not working' actually means

'Not working' can describe very different experiences, and naming yours is the first step to fixing it. Some people mean the scales have not moved. Others mean their appetite feels unchanged, or that they lost well at first and then stalled, or that results are far slower than something they saw online. These have different causes and different answers, so it is worth being precise before changing anything.

Start with the scales, since that is where most worry lives. A single weigh-in is a poor measure on any treatment. Early loss includes water weight, so the trend over weeks matters more than any single weigh-in.² Body weight shifts with salt, hormones, bowel habits and hydration. Weighing at the same time of day, under similar conditions, and looking at the direction across several weeks gives a far truer picture than reacting to a number that rose overnight.

Next, appetite. Tirzepatide activates both GIP and GLP-1 receptors, which together help regulate appetite and slow how quickly the stomach empties.¹ In practice, most people feel fuller sooner and less hungry between meals. But the strength of that effect differs between people and between doses. Feeling only a mild change at a starting dose is common and does not mean the medicine cannot help you at a higher strength.

Then there is the comparison trap. Social media shows the dramatic stories and rarely the quiet ones. Trial results are averages across thousands of people, and a real average always has people above and below it. Measuring yourself against a stranger's highlights is a reliable way to feel that a perfectly normal response is a failure.

Finally, think about what you hoped for. Mounjaro is a licensed weight-management medicine used alongside a reduced-calorie diet and increased physical activity, supplied only after a consultation reviewed by a GPhC-registered prescriber. It is a support for sustained change, not a switch. If your expectation was rapid loss with no change in eating, the disappointment is understandable, but the expectation itself needs adjusting.

Write down what you mean by 'not working' in one sentence, with the date you started, your current dose and how long you have been on it. That single note makes the conversation with your prescriber far more productive. If your situation sounds like those described on our page about Mounjaro that did not work for someone, the same checks apply.

05 · Still on a low dose

You may still be on a low dose

Being on an introductory dose is the single most common reason tirzepatide feels weak. Treatment starts low on purpose and steps up over time so that your body can adjust. Mounjaro comes as a pre-filled multi-dose KwikPen in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ The starting strength of 2.5mg is there to ease you in, and it is not intended to be the dose that delivers your full result.

Each pen lasts four weeks, and the dose steps up after at least 4 weeks on each dose, depending on how you respond. Three months in, most people are still on the lower rungs of the dose ladder, so trial-average losses at this stage are modest compared with the headline figures.²

That matters because the trial numbers people quote came from higher strengths over a long period. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² Those results were measured at the end of a long programme, not in the first weeks on the starting pen.

Not everyone needs the top strength. The dose that suits you is the one your prescriber judges effective and tolerable for you, and the maximum is not a target you must reach. But if you have only ever used the starting strength, you have not yet tested what the medicine can do for you. The practical step is to ask at your review whether a step-up is appropriate, based on your progress and how you are tolerating treatment.

The flip side is equally important. Moving up too fast, or asking for a higher pen than you are ready for, can make side effects worse without improving results. That is why titration decisions sit with a prescriber who can see your history.

Our guide to why Mounjaro might not be working goes further on dose-related causes.

06 · Time and realistic pace

Time: the pace is slower than people expect

Many people judge tirzepatide too early. Weight loss on Mounjaro is gradual by design, and the trials measured results over a long period, not days. Trials measured results at 72 weeks — think in months, not days, and judge progress by trend, not individual weigh-ins.² If you are a few weeks in and disappointed, you are very likely comparing yourself with an outcome that takes far longer to build.

What should you expect at around the three-month mark? A sensible three-month expectation on a standard titration is mid single digits as a percentage of body weight, with wide individual variation.² Notice the words 'wide individual variation'. Some people will be ahead of that, some behind, and both groups can still go on to a good result. In SURMOUNT-1, average weight loss built month by month, with the full averages measured at 72 weeks, not at twelve.

The early weeks deserve special mention. The 2.5mg starting weeks are about adjustment, and experiences differ widely: some people notice appetite change and early loss straight away, others feel little until a higher dose — both are normal.² If you fall in the second group, you are not a non-responder. You are someone whose response simply starts later.

There is real reassurance in this: slower early progress does not predict failure — the dose you respond to may still be ahead of you. That sentence is worth remembering when a weigh-in disappoints you.

It also helps to look beyond the scales. In trials, weight loss on tirzepatide came with average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels.² These are trial-average secondary outcomes, not promises, but they show why progress can be real before the scale reflects it. Clothes fit, energy, appetite and blood-test results can all move first.

Practical ways to judge time fairly: keep a simple record of weekly weight, measurements and how hungry you feel; compare the trend across a month rather than a day; and note when you last changed dose, since each step needs time to show its effect. The free GLPTrackr companion app can help you log this.

For more on pacing, our page on whether Mounjaro will work for you sets out what a typical journey looks like.

07 · Plateaus and adaptation

Plateaus: stalls are normal, not failure

A plateau of a few weeks is a normal part of losing weight on tirzepatide, not proof that it has stopped working. Weight loss on Mounjaro is not linear — plateaus of a few weeks are normal and expected as the body adapts to a lower weight.² A lighter body needs less energy, so the same food that once produced a deficit may now roughly balance. That alone can flatten a graph that was heading down.

Plateaus feel worse than they are because they arrive just when you are most invested. You have seen the scale fall, you have changed your habits, and then nothing moves for a while. The temptation is to assume the medicine has worn off.

So what should you do? Within the licence, the responses are practical and unglamorous. Review food intake honestly, because portions drift back up. Protect protein and activity. Check the basics, including sleep and alcohol. And discuss with your prescriber whether a dose step-up is appropriate if you are not yet at maximum.² That order matters: audit first, then consider the dose.

The 'calorie creep' idea is worth taking seriously, even though it sounds boring. With reduced hunger, it is easy to graze on small, calorie-dense items, to drink calories in coffees or juices, or to enlarge portions slowly without noticing. Because the medicine reduces how often you feel hungry rather than removing eating altogether, what you choose to eat still sets the outcome. A week of honest food logging often reveals more than any amount of worrying.

Also separate a true plateau from a short blip. Hormonal cycles, travel, constipation, salt-heavy meals and a hard training session can all raise the scale temporarily. Wait until you have a clear run across several weeks before calling it a stall.

What you should not do is overreact. A plateau is not a reason to double doses or add unlicensed products. Doubling up raises the risk of side effects and sits outside the licence, and unlicensed add-ons carry unknown risks. If a stall persists, a review call is the safer route, and our page on why Mounjaro does not work for some people explores variation between individuals.

08 · Food, protein and habits

Food, protein, sleep and alcohol

Habits decide how far tirzepatide takes you, because it is used alongside a reduced-calorie diet and increased physical activity, not instead of them. These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.² That does not mean you must be perfect. It means the medicine and your routine pull together, and when one slips, the result slows.

Begin with food. Reduced appetite makes it easier to eat less, but it does not choose what you eat. Smaller meals made of convenient, calorie-dense foods can still add up. Liquid calories are easy to overlook, as are snacks eaten out of habit rather than hunger. A short run of honest logging, even for a couple of weeks, shows where the energy is actually going. Portions drift back up, and catching that early is usually enough to restart progress.

Protein deserves particular attention. When you eat less overall, it is easy to eat too little protein, which can leave you hungrier and less satisfied. Protecting protein alongside activity supports the way your body responds to weight loss. Your prescriber or a dietitian can advise how much suits you.

Activity matters in two ways. It supports health and weight management directly, and it helps you keep the habits that sustain loss. You do not need an extreme programme. Regular walking, strength work you enjoy and a routine you can keep are far more useful than bursts you abandon within weeks.

Then the basics: sleep and alcohol. Poor sleep can make hunger harder to manage and decisions about food harder to stick to. Alcohol adds calories, can lower your guard around food and may worsen how you feel on treatment. Neither is dramatic, but both are the sort of everyday factors that quietly flatten progress.

It is also worth being kind to yourself. Many people on tirzepatide feel guilt when results slow, as though they are letting the medicine down. The medicine is a tool, and tools work best with a steady, realistic routine rather than punishing rules. Aim for habits you could still follow in a year.

If you want a structured way to track all this, the GLPTrackr companion app is free for iOS and Android, and our monthly reviews give you a point to talk through food, activity and progress with the prescribing team.

09 · Why responses differ

Why responses differ between people

Tirzepatide does not work identically for everyone. Trials report averages, and averages describe a group, not you. In SURMOUNT-1, most participants lost a meaningful amount, and the proportions losing at least five percent were high at every dose, but the same data contain people who lost much less than the average. Your own result may sit above or below the trial figure, and trial averages do not predict your own result.

Why might this be? The mechanism offers part of the answer. Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin. Individual biology differs from person to person, and it is not possible to predict who will respond most.

Other factors are practical rather than biological. The dose you have reached, how long you have been on it, how closely your habits support it, and how well you are tolerating treatment all shape the outcome. Side effects can also limit how far you can step up. If nausea or other effects stop you moving to a higher strength, the response you see at a lower strength may be smaller.

It is also worth separating 'responds less' from 'does not respond'. Most people who say it is not working are, on closer review, responding but more slowly than hoped, or responding in ways the scale does not capture yet. A true absence of any appetite or weight response after a fair trial at an appropriate dose is much less common, and it deserves a proper clinical conversation rather than guesswork.

What about the trial result you keep seeing? The headline of roughly one fifth body weight lost came from the highest strength over a long period, and the same trial shows lower averages at lower strengths. Quoting only the highest figure to someone who has used the starting pen for a few weeks sets them up for disappointment.

If you are concerned, the sensible path is a review with your prescriber, who can consider your dose, tolerability and progress together. Our related guide on why Mounjaro might not work for you adds further context, and the patient information leaflet explains what to expect from the medicine.¹³

10 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

11 · Review and next steps

When to speak to your prescriber, and your options

Speak to your prescriber when you have given a sensible dose a fair trial, checked the basics and still see little change. There is also a formal checkpoint. Treatment response is reviewed by your prescriber: if you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.² That is a conversation, not an automatic verdict, and the 'highest tolerated dose' wording matters: it is about what you can tolerate, not forcing the maximum.

Bring useful information. Note your start date, each dose and when you changed it, your weekly weights, how your appetite feels, and any side effects. Mention whether food, sleep, alcohol or activity have changed. This lets the prescriber judge whether you need more time, a step-up, a change in approach, or a different decision altogether.

Report new or worrying symptoms promptly. If something new appears that you cannot explain, discuss it with your prescriber and consider reporting it through the Yellow Card scheme.¹⁹ Do not assume a symptom is connected to the medicine, and do not assume it is not.

What about other options? Within the licence, your prescriber may discuss continuing as you are, adjusting the dose, or stopping if the treatment is not right for you. Other licensed weight-management medicines exist, such as the Wegovy pen, and a prescriber can explain whether a different option makes sense for you. Switching is a clinical decision, not a quick fix.

What you should avoid is equally clear. Do not buy from sellers offering to supply without a consultation or prescription, because you cannot be sure what you are getting. A genuine prescription route, such as ours through official LillyDirect supply with a GPhC-registered prescriber review, exists to protect you.

As for the NHS, Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

If you are an existing customer, our ongoing monthly reviews, dose-titration and follow-up assessments by the prescribing team exist for this moment. Repeat orders re-check suitability, and support is available Monday to Friday. For a broader view of the topic, see our weight loss clinic overview.